Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 9 , Pages 672-678 , September 2011

Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production

  • K. Shimada

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
    • ,
  • T. Murayama

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
    • ,
  • M. Yokode

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
    • ,
  • T. Kita

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
    • ,
  • M. Fujita

      Affiliations

    • Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
    • ,
  • C. Kishimoto

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 (075) 751 3197; fax: +81 (075) 751 4281.

Received 21 October 2009 ,Revised 10 December 2009 ,Accepted 31 December 2009.

References 

  1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126
  2. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904–912
  3. Mollnau H, Wendt M, Szöcs K, Lassègue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:e58–e65
  4. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis. Evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027–2033
  5. Yuan Z, Nimata M, Okabe TA, Shioji K, Hasegawa K, Kita T, et al. Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am J Physiol Heart Circ Physiol. 2005;289:H 1147–H 1152
  6. Weinstock JV, Blum AM, Kassab JT. Angiotensin II is chemotactic, for a T-cell subset which can express migration factor activity in murine Schistosomiasis mansoni. Cell Immunol. 1987;107:180–187
  7. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186:402–410
  8. van der Hoorn JM, Kleemann R, Havekes LM, Kooistra T, Princen HM, Jukema JW. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3 Leiden transgenic mice. J Hypertens. 2007;25:2454–2462
  9. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol. 2007;49:1482–1489
  10. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006;70:1717–1724
  11. Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens. 2005;23:1879–1886
  12. Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, et al. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens. 2005;23:1383–1389
  13. Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens. 2002;15:9S–13S
  14. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343–353
  15. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133–140
  16. Kato M, Sada T, Chuma H, Mizuno M, Terashima H, Fukushima Y, et al. Severity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor antagonist apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2006;47:764–769
  17. Murayama T, Yokode M, Kataoka H, Imabayashi T, Yoshida H, Sano H, et al. Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation. 1999;99:1740–1746
  18. Okabe T, Kishimoto C, Shimada K, Murayama T, Yokode M, Kita T. Effects of MCI-186 (Edaravone), a novel free radical scavenger, upon experimental atherosclerosis in apolipoprotein E-deficient mice. Circ J. 2006;70:1216–1219
  19. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995;285:181–188
  20. Miller FJ, GuHerman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res. 1998;82:1298–1305
  21. Shimada K, Murayama T, Yokode M, Kita T, Uzui H, Ueda T, et al. N-acetylcysteine reduces the severity of atherosclerosis in apolipoprotein E deficient mice via reducing superoxide production. Circ J. 2008;73:1337–1341
  22. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation. 2002;106:1403–1409
  23. Miyamoto M, Kishimoto C, Shioji K, Nakamura H, Toyokuni S, Nakayama Y, et al. Difference in thioredoxin expression in viral myocarditis in inbred strains of mice. Jpn Circ J. 2001;65:561–564
  24. Kishimoto C, Shioji K, Nakamura H, Nakayama Y, Yodoi J, Sasayama S. Serum thioredoxin (TRX) levels in patients with heart failure. Jpn Circ J. 2001;65:491–494
  25. Kishimoto C, Kawamata H, Sakai S, Shinohara H, Ochiai H. Role of MIP-2 in coxsackie virus B3 myocarditis. J Mol Cell Cardiol. 2000;32:631–638
  26. Kondo N, Nomura M, Nakaya Y, Ito S, Ohguro T. Association of inflammatory marker and highly sensitive C-reactive protein with aerobic exercise capacity, maximum oxygen uptake and insulin resistance in healthy middle-aged volunteers. Circ J. 2005;69:452–457
  27. Gielen S, Adams V, Möbius-Winkler S, Linke A, Erbs S, Yu J, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol. 2003;42:869–872
  28. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol. 2004;43:1056–1061
  29. Yuan Z, Kishimoto C, Sano H, Shioji K, Xu Y, Yokode M. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol. 2003;285:H899–H906
  30. Shioji K, Kishimoto C, Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res. 2001;89:540–546
  31. Nicoletti A, Kaveri S, Caligiuri G, Bariéty J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest. 1998;102:910–918
  32. Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxidants and antioxidants in atherogenesis: an appraisal. J  Lipid Res. 1999;40:2143–2157
  33. Bernal-Mizrachi C, Gates AC, Weng S, Imamura T, Knutsen RH, DeSantis P, et al. Vascular respiratory uncoupling increases blood pressure and atherosclerosis. Nature. 2005;435:502–506
  34. Franzoni F, Ghiadoni L, Galetta F, Plantinga Y, Lubrano V, Huang Y, et al. Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. Am J Hypertens. 2005;18:510–516
  35. Zhang H, Schmeisser A, Garlichs CD, Plötze K, Damme U, Mügge A, et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH/NADPH-oxidases. Cardiovasc Res. 1999;44:215–222
  36. Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002;105:1429–1435
  37. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:23–28
  38. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996;98:2572–2579
  39. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension. 2005;45:545–551
  40. Ni W, Kitamoto S, Ishibashi M, Usui M, Inoue S, Hiasa K, et al. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2004;24:534–539

☆ Supported in part by research grants from The Univers Foundation, Chiyoda Kenko Organization, The Nakatomi Foundation, and Japanese Ministry of Education, Science, and Culture (18596772).

PII: S0939-4753(10)00015-3

doi: 10.1016/j.numecd.2009.12.016

Nutrition, Metabolism & Cardiovascular Diseases
Volume 21, Issue 9 , Pages 672-678 , September 2011

Article Tools

* Image Usage & Resolution